Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Effexor "broken heart" ads cited by FDA; agency is concerned about post-MI antidepressant promos.

Executive Summary

EFFEXOR AD LETTER REFLECTS FDA CONCERNS OVER POST-MI ANTIDEPRESSANT PROMOS, an issue that also figured in the warning letter FDA's Division of Drug Marketing, Advertising & Communication sent to Pfizer one year ago regarding Zoloft (sertraline). FDA sent a notice of violation letter to Wyeth-Ayerst July 25 concerning journal advertisements for the antidepressant Effexor (venlafaxine) that FDA maintained were "directed to depressed patient with concomitant heart disease."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel